News - Biocon
Dexamethasone | C22H29FO5 | CID 5743 - PubChem
Vorinostat | C14H20N2O3 | CID 5311 - PubChem
FlyBase:Papers with technical advances - FlyBase Wiki
Once-per-week selinexor, bortezomib, and dexamethasone versus twice-per-week bortezomib and dexamethasone in patients with multiple myeloma (BOSTON): a randomised, open-label, phase 3 trial
XPO1/CRM1 is a promising prognostic indicator for neuroblastoma and represented a therapeutic target by selective inhibitor verdinexor | Journal of Experimental & Clinical Cancer Research | Full Text
Selinexor | C17H11F6N7O | CID 71481097 - PubChem
Researchers discover genes that predict good response to blood cancer therapy
News Results - DF/HCC
Cells | Free Full-Text | CellMAPtracer: A User-Friendly Tracking Tool for Long-Term Migratory and Proliferating Cells Associated with FUCCI Systems
Pharmaceuticals | Free Full-Text | Technologies for Direct Detection of Covalent Protein–Drug Adducts
The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents | Haematologica
Mutant NPM1 Maintains the Leukemic State through HOX Expression
Bortezomib | C19H25BN4O4 | CID 387447 - PubChem
Atomic basis of CRM1-cargo recognition, release and inhibition. - Abstract - Europe PMC
Disclosure Goals & Objectives Abbreviations
Frontiers | Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell therapeutic armamentarium of relapsed or refractory multiple myeloma
Selinexor - Wikipedia
SBGrid Consortium - Tales - Yuh Min Chook - University of Texas Southwestern Medical Center
CovBinderInPDB: A Structure-Based Covalent Binder Database | Journal of Chemical Information and Modeling
CovBinderInPDB: A Structure-Based Covalent Binder Database | Journal of Chemical Information and Modeling
Mutant NPM1 Maintains the Leukemic State through HOX Expression - ScienceDirect
Mutant NPM1 Maintains the Leukemic State through HOX Expression - ScienceDirect
Oral Selinxor – First-In-Class Anti-Cancer Agent
